NDMM at EHA 2024

CME

Experts Discuss Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes Test 1

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: September 17, 2024

Expiration: September 30, 2025

Michele Cavo
Michele Cavo, MD
Francesca Gay
Francesca Gay, MD, PhD
John Mascarenhas
John Mascarenhas, MD
Josie Montegaard
Josie Montegaard, MSN, AGPCNP-BC
Paul G. Richardson
Paul G. Richardson, MD
Timothy Scialla
Timothy Scialla, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the PURPOSE 1 study in cisgender women, compared with background HIV incidence, HIV incidence was:

2.

Your colleague asks you whether there are data to support efficacy and acceptability to use LA CAB + RPV in adolescents with HIV. You tell them that, at Wk 48 of the IMPAACT 2017 study, there were:

3.

Your colleague asks about evidence behind switching a virologically suppressed person to an INSTI-based regimen. You advise them that, in the PASO-DOBLE study, switching to DTG/3TC compared with BIC/FTC/TAF resulted in:

4.

I am familiar with data from the AIDS 2024 conference, and I plan to translate these data into current or future management strategies.